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Aberrant regulation of the erythroblastosis oncogene B (ErbB) family of receptor tyrosine kinases (RTKs) and 
their ligands is common in human cancers. ErbB3 is required in luminal mammary epithelial cells (MECs) for 
growth and survival. Since breast cancer phenotypes may reflect biological traits of the MECs from which they 
originate, we tested the hypothesis that ErbB3 drives luminal breast cancer growth. We found higher ERBB3 
expression and more frequent ERBB3 gene copy gains in luminal A/B breast cancers compared with other 
breast cancer subtypes. In cell culture, ErbB3 increased growth of luminal breast cancer cells. Targeted deple-
tion of ErbB3 with an anti-ErbB3 antibody decreased 3D colony growth, increased apoptosis, and decreased 
tumor growth in vivo. Treatment of clinical breast tumors with the antiendocrine drug fulvestrant resulted 
in increased ErbB3 expression and PI3K/mTOR signaling. Depletion of ErbB3 in fulvestrant-treated tumor 
cells reduced PI3K/mTOR signaling, thus decreasing tumor cell survival and tumor growth. Fulvestrant treat-
ment increased phosphorylation of all ErbB family RTKs; however, phospho-RTK upregulation was not seen 
in tumors treated with both fulvestrant and anti-ErbB3. These data indicate that upregulation of ErbB3 in 
luminal breast cancer cells promotes growth, survival, and resistance to fulvestrant, thus suggesting ErbB3 as 
a target for breast cancer treatment.
Introduction
Aberrant regulation of the erythroblastosis oncogene B (ErbB) 
family of receptor tyrosine kinases (RTKs) and their ligands is 
common in human cancers (1–4). This family consists of 4 relat-
ed members, HER1/ErbB1/EGFR, HER2/ErbB2/Neu, HER3/
ErbB3, and HER4/ErbB4. Except for ErbB3, which has very weak 
kinase activity, the ErbB RTKs exhibit dimerization-induced 
tyrosine phosphorylation and catalytic activation that results 
in signal transduction to intracellular targets. ErbBs are able to 
form homodimers as well as heterodimers with other corecep-
tors of the ErbB family. ErbB3 relies on transphosphorylation 
by heterodimeric partners to induce signal transduction (5–7). 
Therefore, therapeutic interest in the ErbB family has been his-
torically focused on EGFR and ErbB2.
HER2/ErbB2 is gene amplified in nearly 25% of all breast cancers. 
Targeting HER2/ErbB2 activity using the monoclonal antibody 
trastuzumab or the small molecule tyrosine kinase inhibitor (TKI) 
lapatinib decreases growth of HER2-amplified breast cancer cells, 
improving survival and outcome of patients with breast cancers. 
Recently, clinical results demonstrate that therapeutic resistance to 
HER2/ErbB2 inhibitors occurs in part due to feedback upregulation 
of ErbB3 signaling, increasing the activity and output through the 
PI3K/mTOR pathway. This observation may underlie the recently 
published clinical success of the monoclonal antibody pertuzum-
ab, which targets HER2/ErbB2 and prevents its heterodimerization 
with ErbB3 (8). It was recently demonstrated in genetically engi-
neered mouse models that ErbB3 is required not only for main-
taining the malignant phenotype of HER2/ErbB2-overexpressing 
mammary tumors (9), but also for the genesis of mammary tumors 
that overexpress HER2/ErbB2 and for premalignant changes to the 
mouse mammary epithelium caused by HER2/ErbB2 overexpres-
sion (10), consistent with the idea that HER2/ErbB3 heterodimers 
drive mitogenic signaling in the mammary epithelium.
However, expression analyses suggest that transgenic mouse mod-
els of HER2/ErbB2 overexpression in the mammary epithelium do 
not generate tumors resembling human HER2-enriched breast can-
cers. Instead, these tumors more closely resemble the luminal B sub-
type of human breast tumors (11), those that express estrogen recep-
tor (ER) but are often not responsive to endocrine therapy. Because 
loss of ErbB3 prevented tumorigenesis in these mouse models of 
HER2/ErbB2 overexpression, it is possible that ErbB3 may play a 
wider role in the pathology of luminal B–like tumors that express 
HER2/ErbB2, but that are not necessarily gene amplified. This idea 
is supported by previous demonstrations that ErbB3 was required 
in the untransformed mouse mammary epithelium for growth and 
survival of progenitor and mature luminal cells of the ducts (12), but 
was not required for growth and survival of other epithelial popula-
tions in the mouse mammary gland (13, 14). Because many traits of 
a given breast cancer might reflect the untransformed breast epithe-
lial cell from which the tumor originated (15, 16), these observations 
prompted us to test the hypothesis that ErbB3 drives growth and sur-
vival of luminal breast cancer cells in a manner that parallels its role 
in maintaining the untransformed luminal epithelium. We found 
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that ERBB3 mRNA expression was highest in luminal A/B tumors as 
compared with other clinical breast cancer molecular subtypes. In cell 
culture and xenograft models, targeting ErbB3 using the monoclonal 
antibody U3-1287 (17) impaired tumor cell growth and survival and 
improved tumor response to the ER inhibitor fulvestrant. Specifical-
ly, U3-1287 impaired fulvestrant-mediated compensatory signaling 
through the PI3K/Akt/mTOR pathway. These findings suggest that 
ErbB3 may have therapeutic value in luminal breast cancers.
Results
ERBB3 mRNA expression is highest in luminal breast cancers. Previous 
expression analyses revealed that ERBB3 levels in the human breast 
epithelium are highest in luminal populations as compared with 
other epithelial cell types of the breast (12). To examine ERBB3 
expression across breast cancer molecular subtypes, we used a 
publicly available microarray data set (UNC337) derived from 320 
human breast cancers and 17 normal breast specimens (18). Super-
vised hierarchical clustering of UNC337 using the intrinsic list (19) 
classified breast cancers into 5 molecularly defined subtypes: lumi-
nal A/B, HER2-enriched, basal-like, claudin-low and normal breast–
like (Figure 1A). As expected, HER2-enriched breast cancers bore 
the highest levels of ERBB2 expression, but relatively low EGFR and 
ERBB3 levels. EGFR expression was highest among tumors of the 
basal-like, normal-like, and claudin-low subtypes, which expressed 
the lowest levels of ERBB3. Interestingly, ERBB3 mRNA expression 
was highest among luminal A and luminal B tumors (which are 
Figure 1
ErbB3 expression in luminal breast 
cancers. (A) cDNA microarray analy-
sis of clinical breast cancers (UNC337 
data set). Heat map shows expression 
of EGFR, ERBB2, and ERBB3. Each 
colored square represents relative 
transcript abundance (in log2 space) 
for each sample: lowest expression 
is green, highest is red, and average 
expression is black. The colored array 
tree denotes the intrinsic subtype of 
each sample. Dark blue, luminal A/B; 
green, normal-like; red, basal-like; pink, 
HER2-enriched; yellow, claudin-low). 
(B and C) ERBB3 relative transcript 
levels across intrinsic molecular sub-
types in the UNC337 data set (B) and 
an independently derived microarray 
data subset (C) (20, 21). BL, basal-like; 
CL, claudin-low; H2, HER2-enriched; 
LA, luminal A; LB, luminal B; NL, 
normal-like; Str, stromal. *P < 0.01 
(Student’s t test). Midline shows the 
average ± SD. P values compare 
expression means across all groups. 
Midline shows the average. Whis-
kers show SD. Expression values in 
each tumor are shown by plus signs. 
P values compare expression means 
across all groups. (D and E) Luminal 
breast cancer cells were transduced 
with retrovirus expressing ErbB3-
IRES-RFP. Puromycin-resistant cells 
overexpressing ErbB3 (1 × 103/well) 
were suspended in Matrigel (100 μl), 
cultured 10–14 days, photodocumented 
(D), and quantitated (E) using ImageJ 
software (NIH). Original magnifica-
tion, ×100. Values shown represent the 
average number of colonies/well ± SD. 
n = 3. *P > 0.05; **P > 0.01; ***P > 0.001. 
(F and G) ERBB3 gene copy number 
and mRNA expression levels were 
determined in TCGA-curated luminal A 
and luminal B breast cancers (23) and 
used to organize samples into those 
exhibiting ERBB3 copy number gain 
or high ErbB3 expression (shown in 
red). Overall survival analysis was per-
formed using cBio Portal (22).
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largely ER positive) and lowest in basal-like and claudin-low sub-
types (which are largely ER negative). The average level of ERBB3 
mRNA expression was determined for each molecularly defined 
breast tumor subtype, revealing a significant increase in ERBB3 
mRNA in luminal A and luminal B tumors over HER2-enriched, 
basal-like, claudin-low, and normal-like breast tumors (Figure 1B). 
These observations were verified in independent gene expression 
microarray data of 298 breast tumors (Figure 1C and refs. 20, 21). 
Analysis of clinical breast cancer specimens curated by The Cancer 
Genome Atlas (TCGA) (22, 23) revealed genomic ERBB3 copy num-
ber gains in 12.3% and 21.1% of luminal A and luminal B tumors, 
respectively, and in 27.6% of HER2-enriched breast tumors. How-
ever, ERBB3 copy number gains were seen in only 2.5% of basal-
like tumors and were not detected in claudin-low tumors (Table 1). 
In contrast, ERBB3 copy number losses were detected in 33.3% 
and 25% of basal-like and claudin-low breast tumors, respectively, 
but in only 3%, 1.5%, and 3.4% of luminal A, luminal B, and HER2-
enriched breast tumors, respectively. ERBB3 mRNA expression 
was elevated in luminal A/B tumors exhibiting ERBB3 gene copy 
number gains as compared with those tumors with diploid ERBB3 
(Supplemental Figure 1; supplemental material available online 
with this article; doi:10.1172/JCI66764DS1). Taken together, these 
data demonstrate that in primary breast cancers, ERBB3 mRNA 
expression correlates positively with the luminal A and luminal B 
subtypes, but not basal-like and claudin-low.
Luminal breast cancer cells utilize ErbB3 signaling for cell growth and 
survival. Because ErbB3 was expressed at high levels in luminal 
breast cancers, we examined the role of ErbB3 in luminal breast 
cancer cell lines. First, we overexpressed ErbB3 in ERα-positive 
luminal breast cell lines (Supplemental Figure 2), and cultured 
cells in 3D extracellular matrix (Matrigel) over 10 days (Figure 1D). 
ErbB3 overexpression increased colony growth in HCC1428 
(PIK3CAWTPTENWTHER2WT), MDA-MB-361 (PIK3CAE545KPTENWT 
HER2WT), and BT474 (PIK3CAK111NPTENWTHER2AMP) cells (Figure 1E), 
suggesting that ErbB3 may enhance growth or progression of 
luminal breast tumors. This is consistent with TCGA-curated 
data demonstrating that luminal A breast tumors expressing high 
ErbB3 or with ErbB3 gene copy number gains exhibited decreased 
overall survival as compared with all other luminal A tumors 
(Figure 1F; P = 0.037). A correlation between ErbB3 mRNA/gene 
copy number and patient survival was not observed in luminal B 
breast cancers from the TCGA data set (Figure 1G; P = 0.435).
Next, we tested the response of 3 luminal breast cancer–derived 
cell lines to U3-1287, a fully human monoclonal antibody direct-
ed against the human ErbB3 ectodomain. U3-1287 blocks ligand 
binding of ErbB3 and causes receptor downregulation (Figure 2A 
and ref. 24). Although growth of monolayer cultures of luminal 
breast cancer cell lines was not affected by U3-1287 (Supplemental 
Figure 3), single-cell suspensions of MCF7 (PIK3CAE545KPTENWT 
HER2WT), MDA-MB-361, and T47D (PIK3CAH1047RPTENWTHER2WT) 
cells embedded in Matrigel were growth inhibited over 14 days 
when cultured in the presence of U3-1287 (Figure 2B), result-
ing in decreased number of colonies in each cell line (Figure 2C). 
Based on these results, we assessed the effects of ErbB3 target-
ing of luminal breast tumors in vivo. MCF7, T47D, and MBA-
MB-361 cells were injected into the inguinal mammary fat pads 
of BALB/c nu/nu female mice 24 hours after implantation of slow-
release estrogen pellets. Tumors were palpable at 7–14 days and 
were subsequently measured twice weekly. Once tumors reached 
100 mm3, tumor-bearing mice were randomized into treatment 
groups receiving either U3-1287 (10 mg/kg, twice weekly) or con-
trol human IgG for 4 weeks. Histological analysis revealed that, 
while IgG-treated tumors comprised solid sheets of densely packed 
tumor cells, U3-1287–treated MCF7 tumors harbored large acellu-
lar areas (Figure 2D). Similar results were seen in T47D and MDA-
MB-361 tumors (Supplemental Figure 4). U3-1287 significantly 
slowed the growth rate of MCF7 tumors, resulting in a 2-fold 
decrease in tumor volume as compared with IgG-treated tumors 
after 4 weeks of treatment (Figure 2E). Western analysis of whole-
tumor lysates harvested after 7 days of treatment demonstrated 
that ErbB3 was downregulated in MCF7 tumors treated with 
U3-1287 as compared with those treated with IgG (Figure 2F). 
Similar results were seen in T47D tumor lysates (Supplemen-
tal Figure 5). Tumors treated with U3-1287 displayed modestly 
decreased phosphorylation of Akt (a target of PI3K signaling) 
in MCF7 and T47D lysates and robust inhibition of S6 (a target 
of mTOR signaling) in MCF7 lysates. This observation is consis-
tent with the known role of ErbB3 in activating the PI3K/mTOR 
pathway in numerous ErbB receptor–dependent tumors (25–27), 
although MCF7, T47D, and other luminal breast cancer cells are 
not considered a model of EGFR or HER2 dependence.
Immunohistochemical analyses performed on tumors har-
vested after 7 days of treatment confirmed ErbB3 down-
regulation in U3-1287–treated MCF7 tumors (Figure 2G). 
Immunohistochemical detection of Ki67 was used to identify 
cycling cells within MCF7 xenografts, revealing decreased tumor 
cell proliferation in U3-1287–treated tumors (Figure 2G). The 
number of apoptotic cells, identified in situ using TUNEL, was 
increased in U3-1287–treated tumors as compared with IgG-treat-
ed controls (Figure 2G), suggesting that decreased cell growth and 
increased cell death contributed to the decreased tumor growth 
rate upon ErbB3 targeting with U3-1287. Although previous stud-
ies demonstrated that loss of ErbB3 during normal mammary 
gland development shifted the mammary epithelial population 
toward a more basal-like or mammary stem cell–like phenotype, 
we failed to see elevated expression of molecular markers of mam-
mary stem cells or epithelial-mesenchymal transition in MCF7 
cells treated with U3-1287 for 24 hours (Supplemental Figure 6).
Table 1
ERBB3 copy number in breast cancer subtypes
 Luminial A Luminal B HER2-enriched Basal-like Claudin-low
ERBB3 copy number gain/amplification 29/235 (12.3%) 28/133 (21.1%) 16/58 (27.6%) 2/81 (2.5%) 0/8 (0%)
ERBB3 copy number loss (heterozygous  7/235 (3%) 2/133 (1.5%) 2/58 (3.4%) 27/81 (33.3%) 2/8 (25%) 
 and homozygous deletion)
ERBB3 gene copy numbers were assessed by comparative genomic hybridization in 825 TCGA-curated breast cancers (23) and are shown based on 
PAM50-based molecular subtype classifications. Analysis was performed using cBio Portal (22).
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Fulvestrant-mediated upregulation of ErbB3 occurs at multiple levels.  
Previous studies demonstrated that ErbB3 expression is 
upregulated following fulvestrant treatment of MCF7 cells (28). 
We confirmed these findings in fulvestrant-treated MCF7 cells 
using immunofluorescent detection of ErbB3 (Figure 3A). Fulves-
trant increased the number of cells expressing high levels of ErbB3, 
as measured by flow cytometry of fulvestrant-treated MCF7, 
ZR75-1, T47D, and BT474 cells (Figure 3B). While the number of 
MDA-MB-361 cells exhibiting high ErbB3 levels was unaltered in 
the presence of fulvestrant, perhaps due to the already high per-
centage of cells expressing ErbB3 in this cell line, the average inten-
sity of ErbB3 staining per cell was elevated in fulvestrant-treated 
MDA-MB-361 cells as well as in MCF7, T47D, ZR75-1, and BT474.
Fulvestrant-induced ERα degradation correlated with 
upregulation of total ErbB3 protein expression in several lumi-
nal breast cancer cell lines, including cells with WT PIK3CA 
(HCC-1428), mutant PIK3CA (MCF7), and PTEN loss of func-
tion (ZR75-1, CAMA-1) (Figure 3C). Tyrosine phosphorylation 
of ErbB3 (Y1284) was induced in MCF7 cells within 24 hours of 
fulvestrant treatment (Figure 3D). Similarly, fulvestrant-treated 
PIK3CA-mutant cell lines T47D and MDA-MB-361 cells displayed 
ErbB3 upregulation within 16 hours of fulvestrant treatment 
(Figure 3E). To verify the upregulated species as ErbB3, we used 
siRNA-mediated knock-down of ErbB3, demonstrating impaired 
upregulation of ErbB3 protein expression in fulvestrant-treated 
MCF7 and T47D cells (Figure 3F). These results were confirmed 
by quantitative RT-PCR (qRT-PCR) to detect ERBB3 in MCF7 
cells treated with fulvestrant over a time course of 0–24 hours, 
demonstrating a 3-fold upregulation of ERBB3 mRNA within 
13 hours of fulvestrant treatment (Figure 3G). These finding were 
confirmed in a publicly available microarray data set (GSE14986) 
comparing mRNA expression profiles in DMSO-treated versus 
fulvestrant-treated MCF7 cells, revealing a 2.4-fold upregulation 
of ERBB3 after 24 hours (Figure 3H). Transcripts encoding the 
ErbB3 ligand neuregulin-4 (NRG-4) and the ErbB3 heterodimeric 
partners ErbB2 and ErbB4 were also elevated 1.5-fold to 2.3-fold 
in response to fulvestrant, although transcript levels of EGFR and 
NRG-1, -2, and -3 were not statistically altered by fulvestrant in 
this data set. Interestingly, PA2G4, the gene encoding ErbB3 bind-
ing protein (EBP) was downregulated in response to fulvestrant. 
EBP is a known negative regulator of ErbB3 signaling, although 
the mechanism by which this occurs is unclear. However, these 
expression changes predict that fulvestrant induces a transcrip-
tional program that favors ErbB3 signaling. Consistent with these 
results, MCF7 cells transfected with a luciferase reporter driven 
by the proximal 1000 nucleotides upstream of the human ErbB3 
transcriptional start site, pGL-ErbB3 (24), revealed a dose-depen-
dent increase in ErbB3 transcription after 24 hours in the presence 
of fulvestrant (Figure 3I).
Actinomycin D treatment was used to inhibit de novo transcrip-
tion, allowing us to measure how fulvestrant may affect ERBB3 
mRNA stability. Although 50% of ERBB3 transcripts decayed 
within 8 hours of actinomycin D treatment in DMSO-treated cells 
(Figure 3J), ERBB3 mRNA was not reduced in fulvestrant-treated 
cells after 8 hours of actinomycin D, consistent with increased sta-
bility of ERBB3 transcripts in response to fulvestrant. Stability of 
ErbB3 protein was also enhanced in fulvestrant-treated cells, as dem-
onstrated by measuring ErbB3 protein levels after treatment with 
an inhibitor of new protein synthesis, cycloheximide (Figure 3K). 
Thus, upregulation of ErbB3 expression in response to fulvestrant 
occurs at multiple levels of regulation, including transcriptional 
(Figure 3I), posttranscriptional (Figure 3J), and posttranslational 
(Figure 3K), although the precise mechanism by which ErbB3 is 
upregulated will require further investigation.
The impact of increased ErbB3 expression on tumor cell 
response to fulvestrant was examined in luminal breast cancer 
cell lines transduced with lentiviral ErbB3-IRES-RFP, or with 
RFP lentivirus. Single-cell suspensions were cultured 14 days in 
Matrigel in the presence of DMSO or fulvestrant (1 μM) (Figure 4). 
Fulvestrant decreased colony growth in all RFP-expressing cell 
lines tested. However, the cells expressing ErbB3 were resistant to 
growth inhibitory effects of fulvestrant.
Fulvestrant-mediated upregulation of ErbB3 is counteracted by U3-1287. 
To determine the impact of ErbB3 targeting in fulvestrant-treated 
cells, we first confirmed ErbB3 downregulation by U3-1287 in the 
presence and absence of fulvestrant. ErbB3 expression was down-
regulated in MCF7 and MDA-MB-361 cells treated with U3-1287, 
both in the presence and absence of fulvestrant (Supplemental 
Figure 7). Interestingly, downregulation of ErbB3 with U3-1287 
resulted in decreased Tyr1056 phosphorylation of ErbB4, an NRG 
receptor and heterodimeric partner of ErbB3, without affecting 
total ErbB4 levels under basal conditions or upon fulvestrant-
induced upregulation of ErbB4 (Supplemental Figure 8). These 
findings are significant, as previous studies demonstrate that 
ErbB3 and ErbB4 upregulation in response to fulvestrant drives 
NRG-mediated therapeutic resistance to fulvestrant (28). We 
confirmed that NRG/heregulin β1 (2 ng/ml) increased MCF7 
monolayer growth in the presence of fulvestrant (Supplemen-
tal Figure 9). Although U3-1287 alone did not affect monolayer 
growth of MCF7, MDA-MB-361, and T47D cells, the combina-
tion of fulvestrant with U3-1287 decreased cell growth to a greater 
extent than fulvestrant alone (Supplemental Figure 10). Further, 
U3-1287 blocked NRG-mediated resistance to fulvestrant, suggest-
ing that NRG requires ErbB3 to promote resistance to fulvestrant.
We further assessed the impact of U3-1287 on luminal breast 
tumor cell response to fulvestrant using single-cell suspensions 
cultured in 3D Matrigel. Single-agent U3-1287 reduced colony 
Figure 2
Pharmacological downregulation of ErbB3 decreases growth of lumi-
nal breast cancer cells. (A) Cells were cultured in medium with 10% 
serum plus U3-1287 (5 μg/ml) or isotype-matched human IgG for 
24 hours, then used for Western blot analysis of whole-cell lysates 
using antibodies against ErbB3 and E-cadherin. (B and C) Cells were 
cultured in Matrigel for 14 days with the anti-ErbB3 antibody U3-1287 
or isotype-matched human IgG. Colonies were imaged by photomi-
croscopy (B) and quantitated (C) using ImageJ software (NIH). Original 
magnification, ×100 (B). Representative images are shown in B. Values 
shown (C) are average ± SD, n = 3 per treatment group. **P < 0.01; 
***P < 0.001. (D–F) MCF7 tumor-bearing mice were randomized to 
receive normal human IgG or U3-1287 (5 mg/kg twice weekly). (D) 
Histological analysis of tumors on treatment day 28. Scale bars: 50 μm; 
Original magnification, ×400. (E) Average tumor volume ± SD for each 
treatment group is shown, n = 10. P value calculated using Student’s 
t test to compare tumor volumes at day 28. (F) Whole-tumor lysates 
were assessed by Western analysis. Antibodies are shown at right. (G) 
Immunohistochemical detection of ErbB3-, Ki67-, and TUNEL-positive 
cells (arrows) is shown in tumor samples collected after 8 days of treat-
ment. Representative images are shown. Scale bars: 50 μm. Values 
shown are the average ± SD of [(number of Ki67+ or TUNEL+) ÷ (num-
ber of epithelial tumor cells]. n = 5 samples, 4 fields per sample, Stu-
dent’s unpaired t test.
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growth (Supplemental Figure 11) and decreased total colony area 
in 3 of 6 cell lines tested (Figure 5A). While fulvestrant decreased 
colony growth in each of the 6 cell lines, the addition of U3-1287 
resulted in a greater inhibition in total colony area as compared 
with what was seen with fulvestrant alone (Figure 5A), suggesting 
that fulvestrant-induced ErbB3 upregulation and signaling limits 
the potential therapeutic response to fulvestrant.
ErbB3 targeting using U3-1287 increases the response of luminal breast 
cancer cells to fulvestrant in vivo. MCF7 and MDA-MB-361 xenografts 
established in female nude mice supplanted with slow-release estro-
gen pellets were treated weekly with fulvestrant, with and with-
out twice weekly U3-1287 treatment (10 mg/kg). Tumor volume 
was measured twice weekly during 42 days (MCF7) and 21 days 
(MDA-MB-361) of treatment. While MCF7 tumor growth was 
slowed by treatment with U3-1287 on its own and was also slowed 
by treatment with fulvestrant alone, the combination of fulvestrant 
with U3-1287 decreased tumor growth to a greater extent than 
that seen in tumors treated with either agent alone (Figure 5B). 
MCF7 tumor weight was 2.1-fold higher after 42 days of fulves-
trant as compared with what was seen after 42 days of fulvestrant 
plus U3-1287 (Supplemental Figure 12). Similarly, MDA-MB-361 
tumor growth was slowed by fulvestrant alone. However, the com-
bination of fulvestrant plus U3-1287 decreased MDA-MB-361 
tumor growth (Figure 5B) to a greater extent that fulvestrant alone 
and produced a 7-fold reduction in total tumor weight after 21 days 
of treatment (Supplemental Figure 13).
Histological examination of MCF7 tumors harvested at treat-
ment day 42 revealed solid sheets of densely packed tumor cells 
in IgG-treated tumors (Figure 5C). The combination of fulves-
trant with U3-1287 resulted in tumors comprising abundant 
extracellular matrix and sparse tumor cellularity. Similar histo-
logical effects were seen in T47D and MDA-MB-361 xenografts 
treated 14 days with the combination of U3-1287 and fulvestrant 
(Supplemental Figure 14).
Figure 3
Upregulation of ErbB3 signaling upon ER inhibition in luminal breast cancer cells. (A and B) Immunofluorescence (A) and flow cytometry (B) of 
ErbB3 in cells cultured for 24 hours with or without fulvestrant. Original magnification, ×200. (B) Left panel shows the ErbB3hi percentage of cells 
(n = 50,000). Right panel shows average fluorescent intensity per cell. (C–E) Western blot analysis of cell lysates harvested after 0–72 hours of 
1 μM fulvestrant. (F) Cells transfected with ErbB3-siRNA or control-siRNA were treated 24 hours with fulvestrant or DMSO prior to Western blot 
analysis for ErbB3 and ERα. (G) Real-time qPCR analysis of ERBB3 in cells treated 0–24 hours with fulvestrant (1 μM). Average relative ErbB3 
levels shown ± SD. *P < 0.05, 1-way ANOVA. (H) Increased mRNA encoding ErbB receptors and ligands ± SD in fulvestrant-treated MCF7 cells 
measured in publicly available expression data (GSE14986). (I) MCF7 cells transfected with a human ERBB3 gene promoter (–1000/+1) lucifer-
ase reporter plasmid were treated with increasing fulvestrant doses for 24 hours. Average (n = 3) RLUs per μg protein ± SD are shown. One-way 
ANOVA. (J) Real-time qPCR analysis of ERBB3 mRNA in MCF7 cells treated 24 hours ± fulvestrant and actinomycin D (ActD). Average fold change 
is shown ± SD. ***P < 0.001. (K) Western blot analysis of fulvestrant-treated MCF7 lysates. Cycloheximide (CHX) was added for the final 0–4 hours.
Figure 4
ErbB3 expression renders luminal breast cancer cells resistant 
to growth inhibitory effects of fulvestrant. Cells expressing lenti-
viral ErbB3-RFP or RFP alone were cultured 14 days in Matri-
gel ± fulvestrant. Original magnification, ×100. Average number 
of colonies ± SD was evaluated. n = 5. One-way ANOVA.
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We used phospho-histone H3 immunohistochemistry (IHC) 
to detect mitotic cells. The proportion of phospho-histone H3+ 
MCF7 tumor cells was reduced upon treatment with fulvestrant 
alone for 7 days (Figure 5, D and E). Although U3-1287 did not 
reduce phospho-histone H3+ cells in MCF7 tumors, the combina-
tion of U3-1287 with fulvestrant produced a profound reduction 
in phospho-histone H3+ cells (Figure 5E). While MCF7 tumors 
treated with either fulvestrant or U3-1287 displayed an increase 
in TUNEL+ cells as compared with IgG-treated controls, the com-
bination of fulvestrant with U3-1287 significantly increased the 
proportion of tumor cells that were TUNEL+ over what was seen 
with either agent alone (P < 0.01 for either U3-1287 or fulvestrant 
compared with fulvestrant plus U3-1287). These results demon-
strate that the combinatorial targeting of ER and ErbB3 produces 
superior inhibition of tumor growth through decreased tumor cell 
proliferation and survival.
Fulvestrant-mediated ErbB3 upregulation increases PI3K/mTOR sig-
naling. Abundant evidence demonstrates that increased mTOR 
signaling drives resistance to endocrine inhibitors, an observation 
that underlies the clinical success of mTOR inhibitors (RAD001/
everolimus) in combination with endocrine therapies (29). How-
ever, the mechanisms responsible for mTOR signaling in response 
to fulvestrant remain unclear. Because mTOR is a critical effec-
tor of the PI3K pathway and because ErbB3 is a potent activator 
of PI3K signaling, we tested the hypothesis that ErbB3-mediated 
PI3K activation drives mTOR signaling in response to fulvestrant. 
Using phosphorylation of ribosomal protein S6 (P-S6) as a surro-
gate marker of mTOR complex 1 (mTORC1) signaling, we found 
that fulvestrant-mediated ERα degradation coincided with P-S6 
upregulation in MCF7, CAMA-1, T47D, and HCC1428 (Figure 6A) 
and MDA-MB-361 cells (Figure 6B). Fulvestrant-induced phos-
pho-S6 was not seen in cultures treated with the mTORC1 inhibi-
tor RAD001 for the final 2 hours of culture, confirming that ful-
vestrant induces S6 phosphorylation through increased mTORC1 
signaling. This is consistent with the clinical observations that 
RAD001 improves clinical response to endocrine therapies (aro-
matase inhibitors) used to treat luminal breast cancers in the 
neoadjuvant setting (29). Heightened S6 phosphorylation was 
also seen in MCF7 xenografts after 7 days of fulvestrant treatment 
(Supplemental Figure 15).
mTORC1 is a downstream target of the PI3K/Akt pathway, but 
can be engaged by alternative signaling pathways as well. There-
fore, to determine whether fulvestrant-induced ErbB3 signaling 
promotes mTOR activity through the PI3K pathway, we used 
small molecular weight kinase inhibitors to block precise steps 
in the PI3K/mTOR signal transduction cascade for the final 
2 hours of culture. The Akt inhibitor MK2206 (1 μM) and the PI3K 
inhibitor BKM120 (0.5 μM) blocked fulvestrant-induced P-S6, 
suggesting that mTOR is activated downstream of PI3K/Akt in 
fulvestrant-treated cells (Figure 6A). The MEK inhibitor U0126 did 
not affect P-S6 upregulation in response to fulvestrant. Inhibition 
of PDK, a PI3K-activated kinase that phosphorylates Akt at T308, 
impaired fulvestrant-induced P-S6 (Supplemental Figure 16), 
while inhibition of serum glucose kinase (SGK), another PI3K-
activated kinase, appeared to increase S6 phosphorylation under 
basal conditions and did not affect P-S6 levels in fulvestrant-treat-
ed cells. These data suggest that fulvestrant-treated cells upregu-
late mTORC1 through the PI3K-PDK-Akt signaling axis. Because 
ErbB3 is a potent activator of PI3K signaling, we examined the 
impact of ErbB3 inhibition with U3-1287 on fulvestrant-medi-
ated mTOR activation in MCF7 cells. After 24 hours, fulvestrant 
increased phosphorylation of ErbB3 and P-S6 (Figure 6C), but 
U3-1287 blocked S6 phosphorylation in fulvestrant-treated cells. 
These data suggest that ErbB3 signaling drives mTOR activation 
in fulvestrant-treated cells through the PI3K pathway.
To determine whether fulvestrant in combination with ErbB3 
inhibitors might result in growth inhibition comparable to that 
seen with fulvestrant in combination with the mTOR inhibitor 
RAD001, we assessed tumor cell death in cultures treated with 
fulvestrant for 24 hours in the presence of either U3-1287 or 
RAD001 (Supplemental Figure 17). Annexin V staining was used 
to enumerate dying cells, revealing that fulvestrant alone failed 
to increase tumor cell death in MCF7, MDA-MB-361, and T47D 
cells (Figure 6D). U3-1287 as a single agent significantly increased 
the number of annexin V–positive MCF7 and MDA-MB-361 cells 
(P < 0.001 in each cell line), but not T47D cells, but RAD001 failed 
to produce a statistically significant increase in cell death when 
used as a single agent in any cell line tested. In combination with 
fulvestrant, both U3-1287 and RAD001 increased cell death to a 
greater extent than either agent alone. However, the level of cell 
death was greater in response to U3-1287 plus fulvestrant as com-
pared with RAD001 plus fulvestrant.
Previous studies have shown that signaling through mTORC1 
produces negative feedback to the PI3K pathway. This would 
predict that mTORC1 inhibition might relieve this negative feed-
back, resulting in increased PI3K/Akt signaling, an event associ-
ated with therapeutic resistance. This idea was confirmed in MCF7 
and MDA-MB-361 cells cultured with fulvestrant in the presence 
of RAD001, which demonstrated robust Akt phosphorylation at 
T308 (Supplemental Figure 18). However, the combination of 
U3-1287 with fulvestrant reduced Akt phosphorylation at T308 
in both cell lines. These results suggest that ErbB3 targeting in 
combination with fulvestrant may restrain signaling through 
both the PI3K and the mTOR pathways, as opposed to mTOR 
inhibitors, which may allow signaling through the PI3K pathway. 
Because ErbB3 is known to activate PI3K signaling in response to 
ErbB family RTKS and also in response to heterologous RTKs (e.g., 
MET, FGFR2, IGF1R), we performed phospho-RTK array analysis 
Figure 5
Luminal tumor response to the combination of U3-1287 and fulvestrant. 
(A) Luminal breast cancer cells (5 × 103) were embedded in Matrigel 
and cultured 14 days in the presence of U3-1287 (5 μg/ml) or con-
trol IgG with fulvestrant (1 μM) or DMSO. Photodocumented colonies 
were used to quantitate total colony area in ImageJ. Values repre-
sent the average colony area per field ± SD. **P < 0.01; ***P < 0.001. 
(B–E) MCF7 and MDA-MB-361 xenograft–bearing mice were random-
ized into treatment arms to receive U3-1287 or IgG (each at 10 mg/kg, 
twice weekly) in the presence or absence of fulvestrant (once weekly). 
For MCF7 tumors: n = 8 (IgG); n = 6 (fulvestrant + IgG); n = 10 (U3-1287); 
n = 10 (U3-1287 + fulvestrant). For MDA-MB-361 tumors, n = 10 per 
group. Average tumor volumes ± SD are shown. (B) Tumor volume 
was measured throughout the treatment period. *P < 0.05, compar-
ing final tumor volumes, 2-way ANOVA. ***P < 0.001, comparing AUC, 
Student’s t test. (C) Histological analysis of MCF7 tumors after 42 days 
of treatment. Scale bars: 50 μm. (D) Immunohistochemical detection of 
phospho-histone H3+ and TUNEL+ cells in MCF7 tumors after 8 days 
of treatment. Scale bars: 50 μm. (E) The average percentage ± SD of 
phospho-histone H3+ or TUNEL+ MCF7 tumor cells was determined. 
n = 3–4 per condition, 4 random fields per sample. P values calculated 
with 1-way ANOVA.
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tion phase II neoadjuvant trial, in which postmenopausal women 
with newly diagnosed ER-positive breast cancer were treated for 
4 months with anastrozole (Arimidex, an aromatase inhibitor) and 
fulvestrant (Faslodex) (30, 31). After a baseline tumor core biopsy 
on day 0, patients received anastrozole (1 mg daily), and fulves-
trant (250 mg monthly). Pretreatment P-S6 and ErbB3 histo-score 
measurements were compared with P-S6 and ErbB3 histo-scores 
in matched samples from each patient collected after 21 days of 
treatment (Figure 7A). Increased tumor staining for ErbB3 was 
detected following endocrine therapy (n = 4), consistent with our 
results in cell culture models. We also detected increased P-S6 
in ER+ breast tumors following treatment with fulvestrant plus 
anastrozole (Figure 8A). Although the inclusion of the aroma-
tase inhibitor anastrozole is a caveat of the clinical data set that 
is inconsistent with the fulvestrant-specific preclinical modeling 
described herein, these results support the idea that increased 
ErbB3 expression following antiestrogen therapy may be biologi-
cally meaningful. Feedback regulation through signaling path-
ways that utilize ErbB3 may be a mechanism by which luminal 
breast cancers drive PI3K/mTOR signaling to reduce sensitivity to 
hormonal therapy. Importantly, reverse phase protein analysis of 
whole-tumor lysates harvested from 235 luminal A breast tumors 
(TCGA-curated breast tumors) revealed that those tumors exhib-
iting ERBB3 gene copy number gain displayed increased P-S6 and 
increased phosphorylation of p70-S6 kinase as compared with 
those harboring diploid ERBB3 (Figure 8B and ref. 22). These 
results support a model in which ErbB3 signaling through PI3K/
mTOR drives cell growth and survival, even in the face of thera-
peutic ERα inhibition (Figure 8C).
Discussion
Advances in molecular analysis of primary tumors make it clear that 
different subtypes of human breast cancer exist (32). Intense research 
efforts are focused on understanding the molecular characteristics 
defining each group and how those characteristics influence progno-
sis and/or should affect advice regarding treatment decisions within 
a given breast cancer subtype. EGFR overexpression is often found 
in basal-like breast cancers (33). ErbB2/HER2 overexpression due 
to HER2 gene amplification results in formation of HER2-related 
breast cancers (27). There is little consensus about the role of ErbB4 
in models of breast cancer, perhaps due to the multitude of splice 
variations affecting its signaling capabilities and biological outcomes 
or due to its role in promoting secretory differentiation of the breast 
epithelium (34). Because ErbB3 is kinase impaired, its role in breast 
cancer has been framed by its ability to heterodimerize with HER2 
and EGFR (26, 35). ErbB3 tyrosine phosphorylation is often seen 
in ErbB2-overexpressing breast cancers (36, 37). The ErbB2/ErbB3 
heterodimer forms a powerful oncogenic unit, based in part on the 
ability of ErbB3 to amplify signaling through PI3K (4, 26, 38, 39). 
However, we found that ERBB3 mRNA levels were highest in luminal 
A/B breast cancers, a molecular subtype in which ErbB3 signaling 
is relatively understudied. These results are consistent with recent 
findings that ErbB3 is required for cell survival in the untransformed 
luminal mammary epithelium, but not the untransformed basal epi-
thelium (12). Because transformation of a luminal mammary epi-
thelial cell (MEC) may give rise to a luminal breast cancer (15, 16), 
it is possible that the molecular pathways regulating luminal MEC 
development may be commandeered by luminal breast tumors to 
promote growth and survival. Understanding the confluence of 
these signaling pathways will yield a greater understanding of how 
of MCF7 whole-cell lysates cultured 24 hours in the presence of 
fulvestrant (Figure 6E). In addition to increased phospho-ErbB3, 
we found increased tyrosine phosphorylation of several RTKs 
in fulvestrant-treated cells as compared with what was seen in 
DMSO-treated cells, including insulin receptor (IR), IGF-1 recep-
tor (IGF1R), and the ErbB family RTKs EGFR and ErbB2. However, 
ErbB3 targeting with U3-1287 reduced fulvestrant-induced ErbB3 
tyrosine phosphorylation and also interfered with phosphoryla-
tion of EGFR, ErbB2, IGF1R, and IR. Notably, ErbB3 can heterodi-
merize with each of the ErbB family RTKs and has been detected in 
association with IGF1R. These results suggest that ErbB3 may be 
a keystone in fulvestrant-induced compensatory RTK responses. 
Consistent with this idea, expression analyses performed on RNA 
harvested from MCF7 xenografts treated 42 days with fulvestrant 
in the presence or absence of U3-1287 revealed substantial down-
regulation of breast cancer cell-cycle progression genes (MKI67, 
TOP2A, CCNA2, SCGB1D2, TNFAIP2) in tumors treated with the 
combination of U3-1287 and fulvestrant, but not in response to 
either agent when used alone (Supplemental Figure 19).
ErbB3 targeting decreases fulvestrant-induced PI3K/mTOR signaling in 
luminal breast cancer xenografts in vivo. These data suggest that ErbB3 
may be central to feedback signaling that promotes resistance to 
endocrine therapy, particularly through the PI3K/mTOR path-
way. Therefore, we measured ErbB3 and P-S6 levels in fulvestrant-
treated MCF7, MDA-MB-361, and T47D xenografts. Although 
ErbB3 and P-S6 were detected in untreated MCF7 tumors by 
immunohistochemical analysis, profound upregulation of ErbB3 
and P-S6 was seen after 7 days of fulvestrant treatment (Figure 7A), 
consistent with results obtained in clinical samples and in cell cul-
ture. U3-1287 did not appear to affect expression or nuclear localiza-
tion of ERα and did not affect basal P-S6 levels in MCF7 xenografts. 
However, fulvestrant-induced upregulation of ErbB3 and P-S6 was 
largely impaired in the presence of U3-1287, as was phosphoryla-
tion of Akt at S473 in MCF7 xenografts (Figure 7B). Decreased 
phosphorylation of P-S6 and P-Akt was seen in T47D tumor lysates 
(Figure 7C) and MDA-MB-361 tumor lysates (Figure 7D).
We found similar results in paraffin sections of human breast 
tumor biopsies collected as part of a single-stage, single institu-
Figure 6
Fulvestrant-mediated mTOR upregulation requires signaling through 
the ErbB3-PI3K-Akt axis. (A) Western blot analysis of MCF7, CAMA-1, 
T47D, and HCC1428, whole-cell lysates harvested from serum-
deprived cells after treatment for 48 hours with fulvestrant (1 μM), with 
the final 2 hours in the added presence of the mTOR inhibitor RAD001 
(10 nM), the Akt inhibitor MK2206 (1 μM), the PI3K/p110α inhibitor 
BKM120 (0.5 μM), or the MEK inhibitor U0126 (5 μM). Antibodies used 
are indicated at the left of each panel. (B) Western blot analysis of 
MCF7 cells treated for 48 hours with fulvestrant or DMSO, and with 
RAD001 or DMSO for the final 2 hours of culture. Antibodies used are 
indicated. (C) Western blot analysis of MCF7 cells treated with fulves-
trant (1 μM) or U3-1287 (5 μg/ml) for 48 hours prior to collection of 
whole-cell lysates. Antibodies used are indicated. (D) MCF7, T47D, and 
MDA-MB-361 cells were cultured 24 hours in the presence of fulves-
trant (1 μM) or DMSO, U3-1287 (5 μg/ml) or control IgG, and RAD001 
(0.2 μM) or DMSO. FITC-conjugated annexin V was added to the cul-
tured medium to detect apoptotic cells. The number of FITC-labeled 
cells per ×600 field was measured using Scion Image 2.0 software. 
Values shown represent the average ± SD, n = 3. P values calculated 
with 1-way ANOVA. (E) RTK array was used to assess tyrosine phos-
phorylation of multiple RTKs in whole MCF7 tumor lysates.
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Figure 7
Feedback signaling through ErbB3 limits innate tumor response to endocrine therapy but can be targeted with U3-1287. (A) MCF7 xenografts 
treated with U3-1287 or IgG (each at 20 mg/kg, twice weekly) in the presence or absence of fulvestrant (once weekly) were collected at day 8 
of treatment (24 hours after the second fulvestrant treatment). Immunohistochemical analysis was used to detect ErbB3, P-S6, and ERα. Scale 
bars: 50 μm. (B–D) Western blot analysis of tumor xenografts from mice treated with fulvestrant with and without U3-1287 for 8 days. Tumors were 
harvested 24 hours after the final treatment with U3-1287 and fulvestrant. Antibodies used are indicated.
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HER2. Given that ErbB3 on its own has only weak tyrosine kinase 
activity, ErbB3 should not be categorized so readily as equivalent 
to HER2 and EGFR, which are highly active tyrosine kinases that 
phosphorylate downstream targets. Our results demonstrate that 
ErbB3, despite being kinase impaired, is a valid therapeutic target 
even in the absence of HER2 or EGFR overexpression. These obser-
vations will cause breast cancer scientists to reevaluate their precon-
ceptions regarding how ErbB3 affects tumor cell signaling. Since 
ErbB3 relies on transphosphorylation by heterodimeric partners to 
drive signal transduction, the observation that ERBB3 expression is 
highest in breast cancers expressing lower levels of EGFR and ErbB2 
would suggest other tyrosine kinases may phosphorylate ErbB3 in 
luminal breast cells. We postulate 3 plausible scenarios that are not 
mutually exclusive and are likely to operate together. First, ErbB3/
ErbB4 heterodimerization may drive ErbB3 tyrosine phosphoryla-
tion and signal transduction in luminal breast cancers. Notably, the 
highest levels of ERBB4 mRNA are seen in luminal breast tumors 
over other molecular subtypes (40, 41). Secondly, ErbB3 may become 
tyrosine phosphorylated independently of ErbB heterodimeriza-
to prevent and treat breast cancers. We have shown that ErbB3 drives 
growth and survival of luminal breast cancers, which is similar to 
its role in the development of the luminal mammary epithelium. 
It is now presented as a potential therapeutic target to improve the 
response of luminal breast cancers to antihormonal therapy.
Previous reports demonstrate that ErbB3 is important in endo-
crine resistance in luminal breast cancer cells genetically engineered 
to overexpress HER2 or to lack PTEN. However, we describe herein 
that ErbB3 upregulation is not a genetic event that is imposed, select-
ed for, or acquired over time, but instead is a mechanism inherent 
to many luminal breast cancer cells and one that limits therapeu-
tic response to fulvestrant. Therefore, our findings are not limited 
to those breast cancer cells harboring HER2 gene amplification or 
PTEN deletion. We have included numerous luminal cell lines with 
physiological and pathological levels of HER2, EGFR, and PTEN and 
cell lines expressing WT PIK3CA or mutant PIK3CA (Supplemental 
Table 1). We have used large clinical breast cancer data sets to demon-
strate that luminal breast cancers uniformly express ERBB3 mRNA 
levels that exceed what is seen for transcripts encoding EGFR and 
Figure 8
Fulvestrant-treated clinical breast tumors demonstrate ErbB3 and P-S6 upregulation. (A) Matched pairs of clinical breast cancer specimens col-
lected 24 hours prior to treatment (day 0) and 21 days after a single treatment with fulvestrant on day 1 followed by daily treatment with anastro-
zole (day 21) were assessed by IHC. ErbB3 and P-S6 expression was assessed by IHC. Intensity of total ErbB3 immunostaining (cytoplasmic and 
membrane) and P-S6 immunostaining were quantified. Values shown represent the average ± SD (n = 4). P values trended toward significance 
(P = 0.06, Student’s paired t test). A representative matched pair is shown. Scale bars: 50 μm. (B) TCGA-curated luminal A breast cancers were 
separated into those tumors exhibiting ERBB3 copy number gain on those with diploid ERBB3, then assessed for differences in phospho-proteins 
as detected by RPPA analysis. P-S6 and P-S6 kinase were significantly increased in tumors exhibiting ERBB3 copy number gain. (Student’s t test). 
(C) Model of how luminal breast cancers use ErbB3-PI3K signaling to limit their intrinsic sensitivity to fulvestrant. ERα targeting with fulvestrant 
drives ErbB3 upregulation at the cell surface through transcriptional, posttranscriptional, and posttranslational mechanisms. Increased ErbB3 
enhances PI3K signaling through its 6 PI3K interaction motifs. PI3K activates PDK1, which phosphorylates Akt. Once activated, Akt promotes 
mTORC1 activation, driving increased S6-kinase and S6 phosphorylation.
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Cell culture. All human breast cancer cell lines (MCF7, T47D, MDA-
MB-361) were obtained from ATTC and were cultured in DMEM supple-
mented with 10% FBS (Atlanta Biologics) except where indicated as serum-
free. Fulvestrant (Sigma-Aldrich), BKM120 (Novartis), MK-2206 (Selleck 
Chem), PDK1 inhibitor (Calbiochem), RAD001 (Sigma-Aldrich), and 
heregulin-1β epidermal growth factor-like domain (R&D Systems) were used 
where indicated. Colony assays were seeded in 6-well dishes (105 cells/dish) 
and cultured 14 days in DMEM/10% FBS. Cells were fixed in formalin, 
stained with crystal violet, and imaged on a flatbed scanner.
Immunofluorescence. Cells were fixed 10 minutes in 10% formalin, per-
meabilized in 100% methanol, blocked in 3% gelatin, stained with rabbit 
anti-ErbB3 (1:100; Santa Cruz Biotechnologies) and goat anti-rabbit Alexa 
Fluor 488 (1:100) and mounted with VectaStain+ DAPI (Vector Labora-
tories). Images were captured using the ProgRes MF digital camera (Jen-
optiks) mounted on the Motic AE31 microscope. Images were minimally 
processed in Microsoft Publisher (for contrast only).
Flow cytometry. Cells were collected by gentle trypsinization, fixed and 
permeabilized (BD Cytofix/Cytoperm), and stained with phycoerythrin-
conjugated mouse anti-human ErbB3 (1:50; R&D Systems). Data were 
acquired using the FACSCalibur flow cytometer and Cell Quest software. 
50,000 events were assessed per sample by forward and side scatter gating 
performed on software (Cytobank.org).
Immunohistochemical analysis of ErbB3 in clinical breast tumor specimens. Par-
affin sections of human breast tumor biopsies collected as part of a single 
stage, single institution a phase II neoadjuvant trial testing the combined 
effects of anastrozole (Arimidex), fulvestrant (Faslodex), and gefitinib (Ires-
sa) in postmenopausal women with newly diagnosed ER-positive breast 
cancer (30, 31) were assessed by immunohistochemical staining with anti-
bodies against ErbB3 as described previously (24). The pathologist reading 
the results was blinded to the treatment group (day 1 versus 21).
RNA extraction and quantitative RT PCR. See Supplemental Methods.
Statistics. To assess statistical significance in experiments directly com-
paring an experimental group with a control group, Student’s unpaired, 
2-tailed t test was used. To assess statistical significance in experiments 
in which multiple groups were compared across a single condition, 1-way 
ANOVA was used. To compare the response of 2 agents combined to either 
single agent alone, 2-way ANOVA was used. P < 0.05 was considered signifi-
cantly different from the null hypothesis.
Study approval. All animal experimentation was performed in AAALAC-
approved facilities at Vanderbilt University Medical Center. All animal use 
protocols were reviewed and approved prior to experimentation by the 
Institutional Animal Care and Use Committee at Vanderbilt University.
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tion. This idea is supported by observations that ErbB3 can be trans-
phosphorylated by heterologous RTKs, including Met and FGFR2 
(42, 43). Previous findings suggest that ErbB3 activation is rapidly 
induced by IGF-1 signaling, consistent with the idea that IGF1R con-
tributes to ErbB3 phosphorylation in luminal breast cancers (44, 45) 
and together may promote resistance to endocrine therapy (45, 46). 
A third possibility is that low levels of EGFR and/or ErbB2 are suf-
ficient for phosphorylation of ErbB3 and that their upregulation in 
response to fulvestrant drives ErbB3 tyrosine phosphorylation and 
compensatory PI3K signaling.
In summary, higher levels of ErbB3 expression in luminal breast 
cancers (as compared with other breast cancer subtypes) drives 
growth and survival of several ER-positive breast cancer cell lines. 
Upregulation of ErbB3 in response to fulvestrant was seen in clini-
cal breast specimens and was modeled in luminal breast cancer–
derived cells, revealing that ErbB3 targeting improved the thera-
peutic effect of fulvestrant by limiting ErbB3-induced signaling 
through PI3K/mTOR. These findings demonstrate that ErbB3 
targeting using an antibody-based approach may improve the out-
come of patients treated with antiendocrine therapies.
Methods
Human breast tumor gene expression analysis. The publicly available microarray 
data sets queried for tumor gene expression data were the UNC337 (18) and 
the NKI295 (20, 21, 32, 47–49). PAM50 and claudin-low intrinsic subtype cells 
in UNC337 and NKI295 were used as published previously (18). The MAQC-II 
project: human breast cancer (BR) data set constituting 230 breast tumors was 
extracted from GEO (GSE20194) and utilized to compare ERBB3 expression 
among molecular subtypes. TCGA (23) Invasive Breast Cancer data set was 
clustered according to PAM50 subtypes, and corresponding data on ERBB3 
mRNA and gene copy number, patient survival, and phospho-S6 protein levels 
were analyzed using publicly available software on the cBio Portal website (22).
Xenograft experiments. Estrogen pellets (14 days extended release, 0.17 mg 
β estradiol; Innovative Research of America) were implanted subcutane-
ously into 3- to 4-week-old female BALB/c athymic nude mice (Harlan Lab-
oratories). Right and left inguinal mammary fat pads were injected with 
106 MCF7, MDA-MB-361, or T47D cells in 100 μl growth factor–reduced 
Matrigel. Tumors were measured with calipers twice weekly. Tumor-bear-
ing mice were randomized into treatment arms to receive U3-1287 (pro-
vided by U3 Pharma GmbH) or normal human IgG (5 mg/kg, each deliv-
ered twice weekly by intraperitoneal injection) in the presence or absence 
of fulvestrant (Novartis) delivered once weekly by intraperitoneal injection.
Histological analysis. Sections (5-μm) were stained with H&E. In situ TUNEL 
analysis was performed on paraffin-embedded sections using the ApopTag kit 
(Calbiochem). IHC on paraffin-embedded sections was performed using the 
following antibodies as described previously (13): ErbB3, phospho-histone H3, 
and Ki67 (Santa Cruz Biotechnology Inc.), P-S6 (Cell Signaling Technologies), 
and ERα (Neomarkers). Immunodetection was performed using the Vecta-
stain kit (Vector Laboratories) according to the manufacturer’s directions.
Western blotting. Cells were homogenized in ice-cold lysis buffer (50 mM 
Tris, pH 7.4, 100 mM NaF, 120 mM NaCl, 0.5% NP-40, 100 μM Na3VO4, 1X 
protease inhibitor cocktail; Roche). Proteins were used for Human Phos-
pho-RTK array (R&D Systems) according to the manufacturer’s directions 
or were separated on NuPage polyacrylamide gels (Life Technologies) and 
transferred to nitrocellulose membranes. Membranes were blocked and 
probed with antibody as previously described (12). The following primary 
antibodies were used: ErbB3 (C-17, 1:1000; Santa Cruz Biotechnology Inc.); 
Y1197 P-ErbB3 (1:1000; Cell Signaling Inc.); ErbB4 (1:1000; Santa Cruz 
Biotechnology Inc.); α-actin (1:5000; Sigma-Aldrich); MAPK, P-MAPK, S6, 
P-S6, AKT, and S473 P-Akt (1:1000; Cell Signaling Technologies).
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